Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth

Journal of Periodontal Research

Volumn 34, Issue 3, 1999, Pages 145-153

  Kamali, F ^a   Ball, D E ^b   McLaughlin, W S ^b   Seymour, R A ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Drug metabolism; Gingival overgrowth; HPPH; Phenytoin

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYL PYROPHEOPHORBIDE A; 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A; ANTICONVULSIVE AGENT; CHLOROPHYLL; DRUG DERIVATIVE; PHENYTOIN; PHOTOSENSITIZING AGENT; SULFAPHENAZOLE; TOLBUTAMIDE;

ADULT; AGED; ANIMAL; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD; CAT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; EPILEPSY; FEMALE; GINGIVA OVERGROWTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LIVER; MALE; METABOLISM; MICROSOME; MIDDLE AGED; NONPARAMETRIC TEST; RAT; SPECIES DIFFERENCE; WISTAR RAT;

ADULT; AGED; ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; BIOTRANSFORMATION; CATS; CHLOROPHYLL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPILEPSY; FEMALE; GINGIVAL OVERGROWTH; HUMANS; HYDROXYLATION; LIVER; MALE; MICROSOMES; MIDDLE AGED; PHENYTOIN; PHOTOSENSITIZING AGENTS; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC; SULFAPHENAZOLE; TOLBUTAMIDE;

EID: 0033113228     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.1999.tb02235.x     Document Type: Article

References (26)

1. Hassell TM. Epilepsy and the oral manifestations of phenytoin therapy, Myers HM. Monographs in oral science, vol. 9. Basel. Karger 1981;116-202.
2. Panuska HJ, Gorlin RJ, Bearman JE. The effect of anticonvulsant drugs upon the gingiva - a series of analysis of 1048 patients. J Periodontol 1961;13:15-28.
3. Klar LA. Gingival hyperplasia during dilantin therapy: a survey of 312 patients. J Public Health Dent 1973;33:180-185.
4. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg 1972;34:898-906.
5. Dolin H. Dilantin hyperplasia. Mil Surg 1951;109:134-137.
6. Conard GJ, Haavik CO, Finger KF. The relationship of 5,5-diphenylhydantoin metabolism to the species-specific induction of gingival hyperplasia in the rat. Arch Oral Biol 1972;17:311-321.
7. Kapur RN, Girgis S, Little TM, et al. Diphenylhydantoin-induced gingival hyperplasia: its relationship to dose and serum levels. Dev Med Child Neurol 1973;15:483-487.
8. Little TM, Girgis SS, Masotti RE. Diphenylhydantoin-induced gingival hyperplasia: its response to changes in drug dosage. Dev Med Child Neurol 1975;17:421-424.
9. Addy V, McElnay J, Eyre D, et al. Risk factors in phenytoin-induced gingival overgrowth. J Periodontol 1983;54:373-377.
10. Hassell TM, O'Donnell J, Perlman J. et al. Phenytoin-induced gingival overgrowth in institutionalised epileptics. J Clin Periodont 1984;11:242-253.
11. Dahloff G, Modeer T. The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth: a 2-year longitudinal study. J Clin Periodontol 1986;13:845-849.
12. Ishikawa J, Glickman I. Gingival response to the systemic administration of sodium diphenyl hydantoin (Dilatin) to cats. J Periodontol 1961;32:149-158.
13. Steinberg AD, Alvarez J, Jeffay H. Lack of relationship between the degree of induced gingival hyperplasia and the concentration of diphenylhydantoin in various tissues of ferrets. J Dent Res 1972;51:657-662.
14. Staple PH, Reed MJ, Mashimo PA. Diphenylhydantoin gingival hyperplasia in Macaca arctoides: a new human model. J Periodontol 1977;48:325-336.
15. Shafer WG. An attempt to produce gingival hyperplasia in the albino rat by the administration of dilantin sodium. J Dent Res 1948;27:768-769.
16. Swenson HM. A failure to produce enlargement of the gingiva in rats by using dilantin sodium. J Dent Res 1954;33:468.
17. Hassell TM, Page RC. The major metabolite of phenytoin (Dilantin) induces gingival overgrowth in cats. J Periodont Res 1978;13:280-282.
18. Gibson GG, Skett P. Introduction to drug metabolism. London: Chapman and Hall, 1986;241-242.
19. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokin 1979;4:153-169.
20. Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985;12:413-419.
21. Hassell TM, Maguire JH, Cooper CG, Johnson PT. Phenytoin metabolism in the cat after long-term administration. Epilepsia 1984;25:556-563.
22. Kutt H, Verebely K. Metabolism of diphenylhydantoin by rat liver microsomes - I. Characteristics of the reaction. Biochem Pharmacol 1970;19:675-686.
23. Tsuru M, Erickson RR, Holtzman JL. The metabolism of phenytoin by isolated hepatocytes and hepatic microsomes from male rats. J Pharmacol Exp Ther 1982;222:658-661.
24. Doecke CJ, Sansom LN, McManus ME. Phenytoin 4-hydroxylation by rabbit liver P450IIC3 and identification of orthologs in human liver microsomes. Biochem Biophys Res Commun 1990;166:860-866.
25. Nuki K, Cooper SH. The role of inflammation in the pathogenesis of gingival enlargement during the administration of diphenylhydantoin sodium in cats. J Periodont Res 1972;7:102-110.
26. Conard GJ, Osborn JC, Pekary AD, Scholle RH. Relationship of drug metabolism and inflammation to the gingival response of rats treated with diphenylhydantoin. J Dent Res 1975;54(suppl B):B68-B74